News

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
GlobalData on MSN23h
Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in
An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.
Drug Store News6d
Alvotech, Dr. Reddy’s to co-develop Keytruda biosimilar
Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...
Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of ...
The Manila Times19d
Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain ...
NDTV Profit on MSN19d
Dr Reddy's, Alvotech Partner To Develop Biosimilar For Cancer Treatment
Dr Reddy's Laboratories on Thursday said it has joined hands with global biotech firm Alvotech to co-develop and commercialise a biosimilar product for treating multiple types of cancer. The Hyderabad ...
Nasdaq3mon
Alvotech Expands Biosimilar Development Capabilities with Acquisition of Xbrane Biopharma R&D Operations
Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...
Business Insider4mon
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines ...
Morningstar3mon
Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
"Alvotech has a best-in-class biosimilars manufacturing site in Iceland, both for drug substance and drug products. At the same time, our strong in-house R&D capabilities have put Alvotech in a ...
Nasdaq6mon
Alvotech to Join Nasdaq Biotechnology Index (NBI) Effective December 23, 2024
Alvotech, a global biotech company focused on developing biosimilar medicines, announced that its stock will be included in the Nasdaq Biotechnology Index (NBI) as part of the index's annual ...
Morningstar19d
Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds ...
REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”) has completed a private placement of the equivalent of 7,500,000 shares in Swedish Depository ...
Alvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Merck's Keytruda
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to co-develop and commercialize a biosimilar of Merck's (NYSE:MRK) cancer drug ...